| 2026-08-11 | Press release | SELLAS Life Sciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update |
| 2026-05-14 | Press release | Download PDF, SELLAS Life Sciences to Participate in Upcoming Investor Conferences, May 14, 2026, (opens in new window) |
| Press release | SELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update |
| 2026-05-12 | Press release | SELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update |
| Press release | SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update |
| 2026-03-17 | Press release | Download PDF, SELLAS Life Sciences to Present Preclinical Data Highlighting Potent Activity of SLS009 in AML at the 2026 |
| 2026-03-17 | Press release | SELLAS Life Sciences to Present Preclinical Data Highlighting Potent Activity of SLS009 in AML at the 2026 AACR Conferen |
| 2026-03-12 | Press release | Download PDF, SELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS0 |
| 2026-03-12 | Press release | SELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009 |
| 2026-01-14 | Press release | Download PDF, SELLAS Life Sciences Enters Agreement with IMPACT-AML to Expand SLS009 Clinical Program into Europe, Janua |
| 2026-01-14 | Press release | SELLAS Life Sciences Enters Agreement with IMPACT-AML to Expand SLS009 Clinical Program into Europe |
| 2025-12-29 | Press release | SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (A |
| 2025-12-29 | Press release | SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (A |
| 2025-12-07 | Press release | SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR |
| 2025-12-07 | Press release | SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR |
| Press release | SELLAS Life Sciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update |
| 2025-11-12 | Press release | SELLAS Life Sciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update |
| 2025-11-03 | Press release | SELLAS Life Sciences Announces Presentation of Phase 2 Data of SLS009 in Combination with Azacitidine and Venetoclax in |
| 2025-11-03 | Press release | SELLAS Life Sciences Announces Presentation of Phase 2 Data of SLS009 in Combination with Azacitidine and Venetoclax in |
| 2025-10-27 | Press release | SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $31 Mill |
| 2025-10-22 | Press release | SELLAS Life Sciences to Participate in the J.P. Morgan U.S. Opportunities Forum |
| 2025-10-13 | Press release | SELLAS Life Sciences to Present In Vivo Preclinical Data Demonstrating Statistically Significant Survival Benefit of SLS |
| 2025-09-30 | Press release | SELLAS Life Sciences Group to Host Virtual R&D Day on October 29, 2025: Advancing Novel Therapies in Acute Myeloid Leuke |
| 2025-09-11 | Press release | SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $23.6 Mi |
| 2025-08-12 | Press release | SELLAS Life Sciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update |
| 2025-08-07 | Press release | SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Cont |
| 2025-07-15 | Press release | SELLAS Meets All Primary Endpoints in Phase 2 Trial of SLS009 in r/r AML and Receives FDA Guidance to Advance into First |
| 2025-07-07 | Press release | SELLAS Life Sciences Appoints Linghua Wang, MD, PhD, to Scientific Advisory Board |
| 2022-09-15 | Presentation | Galinpepimut-S Update Call |
| 2021-08-17 | Presentation | Virtual Investor Symposium on its Lead Asset, Galinpepimut-S |